StockStory has named three cash-rich companies it says investors should avoid, arguing that a strong cash position does not always signal a healthy business. IPG Photonics holds net cash of $871.3 million, or 27.7% of its market value. The fiber laser maker's sales fell 4.9% a year over five years, and earnings per share dropped faster than revenue. Its shares trade at $73.38, or 35.3x forward earnings. Strategic Education has net cash of $22.04 million, or 1.3% of market value. Domestic student numbers have disappointed over two years, and earnings per share grew only 3% a year over five years. The stock trades at $79.58, or 10x forward earnings. LeMaitre has net cash of $186 million, or 9.7% of market value. Its revenue base of $262.4 million limits its cost leverage. Shares trade at $83.69, or 27.3x forward earnings.

Analysts set USD 110.60 target for LeMaitre Vascular stock. Published on 10/20/2026 at 18:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Nine analysts give LeMaitre a Hold consensus and USD 110.60 target. LeMaitre Vascular stock costs EUR 74.00 on October 20, 2026 at 6:29 p.m. CEST. Hold consensus among nine firms. * Nine research firms held a Hold consensus and an average 12-month target of USD 110.60 on October 15, 2026. * Second-quarter 2026 revenue reached USD 70.38 million, up 9.60 percent year over year, while earnings per share were USD 0.74. * LeMaitre Vascular stock costs EUR 74.00 at Lang & Schwarz on October 20, 2026 at 6:29 p.m. CEST. * LeMaitre Vascular will release third-quarter 2026 results on November 4, 2026. LeMaitre Vascular (ISIN US5255582018) carries a Hold consensus from nine research firms and an average 12-month target of USD 110.60, according to MarketBeat on October 15, 2026. That target stands 32.99 percent above the USD 83.17 Nasdaq price on October 20, 2026, using the same currency. After the Xetra close, LeMaitre Vascular was trading at EUR 74.00 at Lang & Schwarz on October 20, 2026 at 6:29 p.m. CEST. Discover more Source Med Gear Monitor Vitals Invest in Stocks Second-quarter sales rose 9.60 percent. LeMaitre's second-quarter 2026 revenue reached USD 70.38 million, up 9.60 percent from the same quarter a year earlier. The company earned USD 17.05 million, or USD 0.74 in diluted earnings per share, according to LeMaitre Vascular and MarketBeat. Revenue was USD 1.09 million below the USD 71.47 million consensus, while earnings per share missed the USD 0.81 estimate by USD 0.07. Stock sits above its yearly low. The Nasdaq-listed medical device company had a 52-week range of USD 78.22 to USD 118.01 on October 20, 2026. At USD 83.17, the stock was 6.33 percent above its yearly low and 29.52 percent below its yearly high. Trading volume stood at 42,302 shares, while the market capitalization was USD 1.9 billion and the price-to-earnings ratio was 29.17. USD 1.9 billion value and November 4 date. LeMaitre declared a quarterly dividend of USD 0.25 per share in its second-quarter update, equivalent to a 1.20 percent yield, according to MarketBeat. The company said on October 12, 2026 that it will release third-quarter 2026 results after the market close on November 4, 2026, with a conference call at 5:00 p.m. ET, according to LeMaitre Vascular. Target distance frames the valuation. The USD 110.60 consensus target is 32.99 percent above the USD 83.17 Nasdaq price, while the Hold view shows that the target does not represent a uniform analyst stance. For the next scheduled catalyst, the November 4 results will provide the next reported comparison for revenue, earnings and guidance. EUR 74.00 at Lang & Schwarz. LeMaitre Vascular was trading at EUR 74.00 at Lang & Schwarz on October 20, 2026 at 6:29 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of LeMaitre Vascular stock. LeMaitre Vascular stock at a glance. * Company: LeMaitre Vascular, Inc. * ISIN: US5255582018 * Ticker: LMAT * Primary exchange: Nasdaq * Price Lang & Schwarz (as of October 20, 2026, 6:29 p.m. CEST): EUR 74.00 * Market capitalization: USD 1.9 billion (as of October 20, 2026) * 52-week range: USD 78.22-USD 118.01 (as of October 20, 2026) * Sector / Industry: Healthcare / Medical Instruments and Supplies Discover more Track Stock Market Sponsored Ad LeMaitre Vascular stock: new analysis - 22 October. Fresh LeMaitre Vascular information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | US5255582018 | LMAT | boerse | 70376011 | bgmi

LeMaitre Vascular stock hits 52-week low as analysts hold. Published on 10/01/2026 at 11:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Second-quarter revenue rose 9.60 percent to USD 70.38 million. LeMaitre Vascular stock has a USD 110.60 target versus its USD 78.22 low. LeMaitre Vascular (US52567J1079) reached a new 52-week low of USD 78.22 on September 21, 2026, according to the dated market report. As MarketBeat reported on September 21, 2026, analyst sentiment was Hold, with an average price target of USD 110.60. The combination of a fresh yearly low and a target well above that level puts the earnings miss at the center of the stock narrative. Mehr entdecken Unterhaltungsnachrichten Quarterly growth missed expectations. LeMaitre Vascular generated USD 70.38 million in revenue during the second quarter of 2026, compared with a USD 71.47 million consensus estimate. MarketBeat reported that diluted earnings per share were USD 0.74 against a USD 0.81 forecast, while revenue still increased 9.60 percent from the second quarter of 2025. The result shows a clear split between operational growth and near-term execution against expectations. The financial data for the second quarter also show net income attributable to common shareholders of USD 17.05 million and a net profit margin of 24.00 percent. Revenue growth therefore remained positive, but the earnings comparison was weaker than the consensus benchmark used by analysts. Targets stay above the yearly low. The analyst picture is cautious rather than uniformly negative. Six analysts held a Hold view and three rated the stock Buy, producing the USD 110.60 average target cited by MarketBeat on September 20, 2026. Target revisions have not all moved in the same direction. Wells Fargo lowered its price target from USD 104.00 to USD 94.00 and kept an Equal Weight rating in a research report dated August 5, 2026, while the broader consensus remained above the stock's USD 78.22 yearly low. 2026 guidance sets the test. LeMaitre's investor presentation dated August 4, 2026, sets 2026 full-year net sales guidance at USD 280.243 million, compared with adjusted 2025 sales of USD 249.602 million. The presentation also gives guidance for operating income of USD 77.759 million and diluted earnings per share of USD 2.91, versus adjusted 2025 diluted earnings per share of USD 2.38, implying 20.00 percent growth on that adjusted basis. Mehr entdecken Politische Nachrichten Sportnachrichten The same LeMaitre investor presentation identifies 163 sales representatives and 5,300 hospital accounts. It also states that more than 50.00 percent of 23,000 vascular surgeons worldwide use LeMaitre products, giving the guidance a measurable commercial base. Market value remains compressed. LeMaitre Vascular had a market capitalization of USD 1.90 billion and a 52-week range of USD 78.22 to USD 118.01 as of September 30, 2026. The company is listed on Nasdaq under ticker LMAT and operates in healthcare medical instruments and supplies, according to Weiss Ratings. LeMaitre Vascular stock facts. * Company: LeMaitre Vascular, Inc. * ISIN: US52567J1079 * Ticker: LMAT * Primary exchange: Nasdaq * Market capitalization: USD 1.90 billion as of September 30, 2026 * 52-week range: USD 78.22-118.01 as of September 30, 2026 * Sector / Industry: Healthcare / Medical Instruments and Supplies Sponsored Ad These 5 stocks could change everything in 2026 - do you know them? Mehr entdecken Nachrichten-Abonnement Nachrichten-App Börsenkurse anzeigen A brand new special report reveals the 5 most promising stocks for the current year. Find out which assets top analysts have on their radar now and why acting quickly could be decisive. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | US52567J1079 | LMAT | boerse | 70209355 | bgmi